The DRAGON 2 Trial
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorMaastricht University
About this trial
In the randomized controlled DRAGON 2 trial study subjects will be randomized between two arms, PVE alone (control group) and PVE/HVE (interventional group).
Eligibility criteria
Qualifiers
Patients with primarily unresectable/ potentially resectable CRLM with a FLR <30% (<40% in chemotherapy damaged livers)
Patients with non-resected primary CRC may be included if there is an intention to resect the CRC after the liver treatment (liver first approach) or simultaneously during one of the liver procedures.
Patients with resectable or ablatable lung or brain metastases can be included (statement about the resectability of these extrahepatic metastases by a tumor board needs to be available)
18 Years and older
Disqualifiers
Pregnant or lactating female.
Premenopausal females not able or willing to commit to oral contraception
Patients with prohibitive comorbidities, decision made by local team
Any patient with non-resectable or non-ablatable extrahepatic disease
Trial design
Treatments tested in this trial
- Embolization
Treatment groups
348 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov